Inhibrx Biosciences, Inc.
INBX
$89.39
$0.290.33%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -0.52% | -11.17% | |||
| Gross Profit | 0.52% | 11.17% | |||
| SG&A Expenses | 2.44% | 5.63% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.01% | -8.54% | |||
| Operating Income | -0.01% | 8.54% | |||
| Income Before Tax | -1.85% | 6.87% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -1.85% | 6.87% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1.85% | 6.87% | |||
| EBIT | -0.01% | 8.54% | |||
| EBITDA | -0.10% | 8.64% | |||
| EPS Basic | -1.51% | 7.20% | |||
| Normalized Basic EPS | -1.51% | 7.20% | |||
| EPS Diluted | -1.51% | 7.29% | |||
| Normalized Diluted EPS | -1.51% | 7.20% | |||
| Average Basic Shares Outstanding | 0.33% | 0.36% | |||
| Average Diluted Shares Outstanding | 0.33% | 0.36% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||